Cargando…

Bipolar Disorder and Parkinson disease: a 123I-FP-CIT SPECT study

INTRODUCTION: Bipolar Disorder (BD) has been suggested to be a risk factor for development of Parkinson Disease. Psychiatric drugs used as standard treatment of BD includes many drugs that are known to induce drug-induced parkinsonism (DIP). OBJECTIVES: Clinical differentiation between PD and DIP is...

Descripción completa

Detalles Bibliográficos
Autores principales: D’agostino, G., Cascino, G., Landolfi, A. M., Erro, R., Barone, P., Monteleone, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10434513/
http://dx.doi.org/10.1192/j.eurpsy.2023.1090
Descripción
Sumario:INTRODUCTION: Bipolar Disorder (BD) has been suggested to be a risk factor for development of Parkinson Disease. Psychiatric drugs used as standard treatment of BD includes many drugs that are known to induce drug-induced parkinsonism (DIP). OBJECTIVES: Clinical differentiation between PD and DIP is a clinical and scientific crucial result. It might be aided by functional neuroimaging of the dopaminergic nigrostriatal pathway. METHODS: Twenty consecutive BD patients with parkinsonism were clinically assessed and underwent (123)I-ioflupane dopamine transporter SPECT. Imaging data of BD patients with pathological nigrostriatal pathway were further compared to a population of de-novo PD patients. RESULTS: Four BD patients had abnormal scans; they had higher putaminal binding ratio and putamen-to-caudate ratios than PD patients, despite similar motor symptom burden. CONCLUSIONS: in our initial results, up to 20% of BD patients with parkinsonism might have an underlying dopaminergic deficit, which is higher than excepted in the general population. This evidences supports that BD represents a risk factor for subsequent development of neurodegenerative parkinsonism. DISCLOSURE OF INTEREST: None Declared